Rate My Professor Dan Siskind

His research specializations encompass clozapine utilization in treatment-refractory schizophrenia, antipsychotic-induced metabolic disorders, and interventions to improve physical health comorbidities in individuals with severe mental illness, including schizophrenia. Professor Siskind has published over 300 peer-reviewed articles, serving as first author in prestigious journals such as The Lancet, World Psychiatry, The Lancet Psychiatry, British Journal of Psychiatry, and Schizophrenia Bulletin. Notable publications include "The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness" (2019, cited over 1,700 times), "Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis" (2016, British Journal of Psychiatry), "A systematic review and meta-regression of the prevalence and incidence of perinatal depression" (2017, Journal of Affective Disorders, cited over 1,900 times), "Occurrence, prevention, and management of the psychological effects of emerging virus outbreaks on healthcare workers" (2020, BMJ), and "An international adult guideline for making clozapine titration safer" (2022, Pharmacopsychiatry). His scholarship has amassed over 20,950 citations. He has attracted more than $60 million in competitive grants as a named investigator, including over $7 million as Chief Investigator A. Major awards include the NHMRC Emerging Leadership Fellowship (2021–2025), NHMRC Early Career Fellowship (2016–2019), and Queensland Advancing Clinical Research Fellowship (2020–2026). Professor Siskind's contributions have shaped international guidelines for schizophrenia management and clozapine use, enhancing clinical practices globally.